Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist
- 1 November 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 151 (2), 257-265
- https://doi.org/10.1016/j.pain.2010.05.022
Abstract
Pancreatic pain resulting from chronic inflammation of the pancreas is often intractable and clinically difficult to manage with available analgesics reflecting the need for more effective therapies. The mechanisms underlying pancreatitis pain are not well understood. Here, the possibility that interleukin-6 (IL-6) may promote pancreatitis pain was investigated with TB-2–081 (3-O-formyl-20R,21-epoxyresibufogenin, EBRF), a small molecule IL-6 receptor antagonist that was semi-synthetically derived from natural sources. The potential activity and mechanism of TB-2–081 were investigated following the induction of persistent pancreatitis using dibutyltin dichloride (DBTC) in rats. TB-2–081 displaces the binding of IL-6 to the human recombinant soluble IL-6 receptor with apparent high affinity and inhibits IL-6 mediated cell growth. Systemic or oral, but not intrathecal, administration of TB-2–081 reversed DBTC-induced abdominal hypersensitivity in a dose- and time-dependent manner. IL-6 levels were significantly up-regulated in the dorsal root ganglia (DRG) of rats with pancreatitis on day 6 after DBTC injection. IL-6-enhanced capsaicin-evoked release of calcitonin gene-related peptide from cultured DRG neurons was blocked by TB-2–081. Our data demonstrate that TB-2–081 acts as a systemically available and orally active small molecule IL-6 receptor antagonist. TB-2–081 effectively reduces pancreatitis-induced pain through peripheral mechanisms that are likely due to (a) increased expression of IL-6 in the DRG and (b) IL-6-mediated sensitization of nociceptive neurons. The activity of TB-2–081 implicates an important role for IL-6 in sustaining pancreatitis pain. Strategies targeting IL-6 actions through small molecule antagonists may offer novel approaches to improve the therapy of chronic pancreatitis and other chronic pain states.Keywords
Funding Information
- NIH Intramural Research Programs of the National Institute on Drug Abuse (NIDA)
- National Institute on Alcohol Abuse and Alcoholism
- NIH (NS065926, DA023513)
This publication has 42 references indexed in Scilit:
- Role of interleukin-6 in chronic muscle hyperalgesic primingNeuroscience, 2008
- Pain management in chronic pancreatitisWorld Journal of Gastroenterology, 2008
- Opioid dependence and addiction during opioid treatment of chronic painPain, 2007
- Inhibitory Effects of Bufadienolides on Interleukin-6 in MH-60 CellsJournal of Natural Products, 2004
- Empirical models of the proliferative response of cytokine-dependent hematopoietic cell linesBiotechnology & Bioengineering, 2004
- Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate—a novel nonpeptide IL-6 receptor antagonistBiochemical and Biophysical Research Communications, 2004
- Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain11Published on the World Wide Web on 28 August 2000.Brain Research, 2000
- Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic painMolecular Brain Research, 1998
- Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayBiochemical Journal, 1998
- The capsaicin receptor: a heat-activated ion channel in the pain pathwayNature, 1997